{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:00:32Z","timestamp":1762527632860,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:00:00Z","timestamp":1583712000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology Case Reports"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.ajoc.2020.100660","type":"journal-article","created":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T18:07:33Z","timestamp":1584122853000},"page":"100660","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Serum KL-6 elevation in a uveitis patient with Beh\u00e7et's disease treated with adalimumab"],"prefix":"10.1016","volume":"18","author":[{"given":"Takashi","family":"Ono","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiko","family":"Terada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinhee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ajoc.2020.100660_bib1","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"130","author":"Jabs","year":"2000","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajoc.2020.100660_bib2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","article-title":"Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders","volume":"121","author":"Levy-Clarke","year":"2014","journal-title":"Opthalmol."},{"issue":"4-5","key":"10.1016\/j.ajoc.2020.100660_bib3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3109\/08820538.2011.588665","article-title":"The use of biologic agents in the treatment of ocular manifestations of Behcet's disease","volume":"26","author":"Benitah","year":"2011","journal-title":"Semin Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajoc.2020.100660_bib4","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.ophtha.2017.12.039","article-title":"Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: visual III","volume":"125","author":"Suhler","year":"2018","journal-title":"Opthalmol."},{"issue":"10050","key":"10.1016\/j.ajoc.2020.100660_bib5","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"issue":"4 Suppl 84","key":"10.1016\/j.ajoc.2020.100660_bib6","first-page":"S58","article-title":"Adalimumab for treatment of severe Behcet's uveitis: a retrospective long-term follow-up study","volume":"32","author":"Interlandi","year":"2014","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.ajoc.2020.100660_bib7","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/sj.eye.6702352","article-title":"Adalimumab for sight-threatening uveitis in Behcet's disease","volume":"21","author":"Mushtaq","year":"2007","journal-title":"Eye (Lond)"},{"issue":"8","key":"10.1016\/j.ajoc.2020.100660_bib8","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/1346-8138.12918","article-title":"Infliximab and adalimumab, unlike ustekinumab, increase serum KL-6 levels in Japanese patients with psoriasis","volume":"42","author":"Yanaba","year":"2015","journal-title":"J Dermatol"},{"issue":"8","key":"10.1016\/j.ajoc.2020.100660_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005615","article-title":"Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis","volume":"4","author":"Nakashita","year":"2014","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.ajoc.2020.100660_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.resinv.2012.02.001","article-title":"Utility of KL-6\/MUC1 in the clinical management of interstitial lung diseases","volume":"50","author":"Ishikawa","year":"2012","journal-title":"Respir. Investig."},{"issue":"3","key":"10.1016\/j.ajoc.2020.100660_bib11","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10067-015-3167-8","article-title":"Association of serum KL-6 levels with interstitial lung disease in patients with connective tissue disease: a cross-sectional study","volume":"35","author":"Oguz","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.ajoc.2020.100660_bib12","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1365-2796.2011.02459.x","article-title":"KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis","volume":"271","author":"Fathi","year":"2012","journal-title":"J Intern Med"},{"issue":"23","key":"10.1016\/j.ajoc.2020.100660_bib13","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.2169\/internalmedicine.50.5866","article-title":"Serum KL-6 level as an indicator of active or inactive interstitial pneumonitis associated with connective tissue diseases","volume":"50","author":"Doishita","year":"2011","journal-title":"Intern Med"},{"issue":"9","key":"10.1016\/j.ajoc.2020.100660_bib14","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/1346-8138.13837","article-title":"Impact of anti-tumor necrosis factor-alpha agents on serum levels of KL-6 and surfactant protein-D in patients with psoriasis","volume":"44","author":"Hayashi","year":"2017","journal-title":"J Dermatol"},{"issue":"4","key":"10.1016\/j.ajoc.2020.100660_bib15","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0049-0172(79)90004-0","article-title":"Behcet disease (Behcet syndrome)","volume":"8","author":"Shimizu","year":"1979","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.ajoc.2020.100660_bib16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/s10165-012-0658-1","article-title":"A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatology","volume":"23","author":"Takamura","year":"2013","journal-title":"Mod Rheumatol"},{"issue":"3","key":"10.1016\/j.ajoc.2020.100660_bib17","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1164\/ajrccm.165.3.2107134","article-title":"Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases","volume":"165","author":"Ohnishi","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.ajoc.2020.100660_bib18","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1272\/jnms.81.364","article-title":"Serum KL-6 elevation and possible pulmonary involvement in patients with rheumatoid arthritis treated with biological agents","volume":"81","author":"Takahashi","year":"2014","journal-title":"J Nippon Med Sch"},{"issue":"2","key":"10.1016\/j.ajoc.2020.100660_bib19","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3109\/s10165-012-0657-2","article-title":"Elevation of KL-6 serum levels in clinical trials of tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a report from the Japan College of Rheumatology Ad Hoc Committee for Safety of Biological DMARDs","volume":"23","author":"Harigai","year":"2013","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1016\/j.ajoc.2020.100660_bib20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1080\/08820538.2017.1353815","article-title":"Cataract surgery complications in uveitis patients: a review article","volume":"33","author":"Llop","year":"2018","journal-title":"Semin Ophthalmol"}],"container-title":["American Journal of Ophthalmology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993619301951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993619301951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T14:56:56Z","timestamp":1762527416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451993619301951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":20,"alternative-id":["S2451993619301951"],"URL":"https:\/\/doi.org\/10.1016\/j.ajoc.2020.100660","relation":{},"ISSN":["2451-9936"],"issn-type":[{"type":"print","value":"2451-9936"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum KL-6 elevation in a uveitis patient with Beh\u00e7et's disease treated with adalimumab","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajoc.2020.100660","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100660"}}